|
|
Article: Results released from CDP 571 phase III studies in Crohn disease.
- Article from:
- Drug Week
- Article date:
- September 13, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 SEP 13 - (NewsRx.com & NewsRx.net) -- Celltech Group plc (CLL; CCH) announced outline results from a phase III study undertaken to evaluate CDP 571 as a new treatment for active Crohn disease, and also from a further phase III study in steroid-dependent Crohn disease patients.
The principal study, involving 400 patients, assessed the efficacy and safety of CDP 571 in achieving acute clinical responses, and in maintaining responses over 28 weeks. CDP 571 was administered intravenously, at 8-weekly intervals, at a dose of 10mg/kg. Treatment-related benefit was assessed by the numbers attaining a significant reduction in Crohn's disease activity index (CDAI) ...